Patents Assigned to Uniqure Biopharma B.V.
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20220090042
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 24, 2022
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20220002702
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20210238573
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 5, 2021
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20210214704
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: March 26, 2021
    Publication date: July 15, 2021
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20200231958
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 23, 2020
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20200199564
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 25, 2020
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo SIMIONI
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION
    Publication number: 20200190498
    Abstract: Disclosed are a modified FIX (Factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Applicant: uniqure biopharma B.V.
    Inventor: Paolo SIMIONI
  • Factor IX polypeptide mutant, its uses and method for its production
    Patent number: 10465180
    Abstract: Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 5, 2019
    Assignee: uniQure biopharma B.V.
    Inventor: Paolo Simioni
  • FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND METHOD FOR ITS PRODUCTION
    Publication number: 20180258413
    Abstract: Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 13, 2018
    Applicant: uniQure biopharma B.V.
    Inventor: Paolo Simioni
  • Factor IX polypeptide mutant, its uses and method for its production
    Patent number: 9982248
    Abstract: Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 29, 2018
    Assignee: UNIQURE BIOPHARMA B.V.
    Inventor: Paolo Simioni
  • Porphobilinogen deaminase gene therapy
    Patent number: 8697665
    Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: April 15, 2014
    Assignees: Proyecto de Biomedicina CIMA S.L., Uniqure Biopharma B.V.
    Inventors: Antonio Fontanellas Romá, Gloria González Aseguinolaza, Maria Sol Rodriguez Pena, Maria Astrid Pañeda Rodriguez, Jaap Twisk, Jesús Maria Prieto Valtueña, Harald Petry, Sander Jan Hendrik Van Deventer